Brind.

Kardigan licensed a lead drug from Bristol-Myers Squibb, utilizing technology further developed by Mayo Clinic, while studying ataciguat originating at Sanofi.

1 report, 1 independent Updated Jun 17

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Kardigan Bristol-Myers Squibb Sanofi Mayo Clinic

Keep exploring

The entities involved

Kardigan
company in South San Francisco, United States

Nothing else this week.
Bristol-Myers Squibb
American pharmaceutical company
- Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
- FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09
Sanofi
company in Milan, Italy

Nothing else this week.
Mayo Clinic
medical practice and medical research group based in Rochester, Minnesota, United States
- Mayo Clinic researchers presented findings at the ASTRO meeting in Boston.Sat 00:34
- Healthcare architecture is rapidly changing, with robotic procedures underway in Riyadh involving major players like Johnson & Johnson, Mayo Clinic, and Cleveland Clinic.Sat 00:14

Coverage

Newest first; wire copies grouped

Jun 17biopharmadive.com